Krystal Biotech Inc
NASDAQ:KRYS

Watchlist Manager
Krystal Biotech Inc Logo
Krystal Biotech Inc
NASDAQ:KRYS
Watchlist
Price: 190.4 USD 4.45% Market Closed
Market Cap: 5.5B USD
Have any thoughts about
Krystal Biotech Inc?
Write Note

Intrinsic Value

The intrinsic value of one KRYS stock under the Base Case scenario is 113.67 USD. Compared to the current market price of 190.4 USD, Krystal Biotech Inc is Overvalued by 40%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KRYS Intrinsic Value
113.67 USD
Overvaluation 40%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Krystal Biotech Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for KRYS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about KRYS?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Krystal Biotech Inc

Provide an overview of the primary business activities
of Krystal Biotech Inc.

What unique competitive advantages
does Krystal Biotech Inc hold over its rivals?

What risks and challenges
does Krystal Biotech Inc face in the near future?

Has there been any significant insider trading activity
in Krystal Biotech Inc recently?

Summarize the latest earnings call
of Krystal Biotech Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Krystal Biotech Inc.

Provide P/S
for Krystal Biotech Inc.

Provide P/E
for Krystal Biotech Inc.

Provide P/OCF
for Krystal Biotech Inc.

Provide P/FCFE
for Krystal Biotech Inc.

Provide P/B
for Krystal Biotech Inc.

Provide EV/S
for Krystal Biotech Inc.

Provide EV/GP
for Krystal Biotech Inc.

Provide EV/EBITDA
for Krystal Biotech Inc.

Provide EV/EBIT
for Krystal Biotech Inc.

Provide EV/OCF
for Krystal Biotech Inc.

Provide EV/FCFF
for Krystal Biotech Inc.

Provide EV/IC
for Krystal Biotech Inc.

Show me price targets
for Krystal Biotech Inc made by professional analysts.

What are the Revenue projections
for Krystal Biotech Inc?

How accurate were the past Revenue estimates
for Krystal Biotech Inc?

What are the Net Income projections
for Krystal Biotech Inc?

How accurate were the past Net Income estimates
for Krystal Biotech Inc?

What are the EPS projections
for Krystal Biotech Inc?

How accurate were the past EPS estimates
for Krystal Biotech Inc?

What are the EBIT projections
for Krystal Biotech Inc?

How accurate were the past EBIT estimates
for Krystal Biotech Inc?

Compare the revenue forecasts
for Krystal Biotech Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Krystal Biotech Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Krystal Biotech Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Krystal Biotech Inc compared to its peers.

Compare the P/E ratios
of Krystal Biotech Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Krystal Biotech Inc with its peers.

Analyze the financial leverage
of Krystal Biotech Inc compared to its main competitors.

Show all profitability ratios
for Krystal Biotech Inc.

Provide ROE
for Krystal Biotech Inc.

Provide ROA
for Krystal Biotech Inc.

Provide ROIC
for Krystal Biotech Inc.

Provide ROCE
for Krystal Biotech Inc.

Provide Gross Margin
for Krystal Biotech Inc.

Provide Operating Margin
for Krystal Biotech Inc.

Provide Net Margin
for Krystal Biotech Inc.

Provide FCF Margin
for Krystal Biotech Inc.

Show all solvency ratios
for Krystal Biotech Inc.

Provide D/E Ratio
for Krystal Biotech Inc.

Provide D/A Ratio
for Krystal Biotech Inc.

Provide Interest Coverage Ratio
for Krystal Biotech Inc.

Provide Altman Z-Score Ratio
for Krystal Biotech Inc.

Provide Quick Ratio
for Krystal Biotech Inc.

Provide Current Ratio
for Krystal Biotech Inc.

Provide Cash Ratio
for Krystal Biotech Inc.

What is the historical Revenue growth
over the last 5 years for Krystal Biotech Inc?

What is the historical Net Income growth
over the last 5 years for Krystal Biotech Inc?

What is the current Free Cash Flow
of Krystal Biotech Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Krystal Biotech Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Krystal Biotech Inc

Current Assets 713.2m
Cash & Short-Term Investments 588.3m
Receivables 97.3m
Other Current Assets 27.5m
Non-Current Assets 269.2m
Long-Term Investments 105.9m
PP&E 163.1m
Other Non-Current Assets 203k
Current Liabilities 89.5m
Accounts Payable 5.6m
Accrued Liabilities 80.8m
Other Current Liabilities 3.2m
Non-Current Liabilities 6.9m
Other Non-Current Liabilities 6.9m
Efficiency

Earnings Waterfall
Krystal Biotech Inc

Revenue
241.5m USD
Cost of Revenue
-18m USD
Gross Profit
223.5m USD
Operating Expenses
-158.6m USD
Operating Income
65m USD
Other Expenses
-12.6m USD
Net Income
52.4m USD

Free Cash Flow Analysis
Krystal Biotech Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the latest earnings call, Krystal Biotech highlighted a significant revenue increase of $83.8 million for VYJUVEK, following a successful launch that has exceeded $250 million in net revenue since its introduction. The company reported a remarkable gross margin of 92% and net income of $27.2 million or $0.95 per share. Additionally, they narrowed their full-year non-GAAP R&D and SG&A expense guidance to $115-$125 million. With $374 million in cash on hand, and plans to expand globally, including launches in Germany and Japan slated for 2025, Krystal remains optimistic about sustaining growth amid seasonal challenges.

What is Earnings Call?
Fundamental Scores

KRYS Profitability Score
Profitability Due Diligence

Krystal Biotech Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROE is Increasing
40/100
Profitability
Score

Krystal Biotech Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

KRYS Solvency Score
Solvency Due Diligence

Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KRYS Price Targets Summary
Krystal Biotech Inc

Wall Street analysts forecast KRYS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KRYS is 211.93 USD with a low forecast of 196.95 USD and a high forecast of 232.05 USD.

Lowest
Price Target
196.95 USD
3% Upside
Average
Price Target
211.93 USD
11% Upside
Highest
Price Target
232.05 USD
22% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for KRYS?

Click here to dive deeper.

Dividends

Krystal Biotech Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for KRYS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

KRYS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Krystal Biotech Inc Logo
Krystal Biotech Inc

Country

United States of America

Industry

Biotechnology

Market Cap

5.4B USD

Dividend Yield

0%

Description

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 119 full-time employees. The company went IPO on 2017-09-20. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The firm's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

Contact

PENNSYLVANIA
Pittsburgh
2100 Wharton St Ste 701
+14125865830.0
www.krystalbio.com

IPO

2017-09-20

Employees

119

Officers

Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, President of R&D and Director
Ms. Suma M. Krishnan
Executive VP & Chief Accounting Officer
Ms. Kathryn A. Romano
General Counsel & Corporate Secretary
Mr. John Thomas
Vice President of North American Sales & Marketing
Mr. John Karakkal
Head of U.S. Sales & Marketing
Ms. Christine Wilson
Show More
Vice President of Corporate Development
Dr. Stephane Paquette Ph.D.
Director of Human Resources & Operations
Mr. Josh Suskin
Senior VP & GM of Europe
Mr. Laurent Goux
Senior Vice President of Clinical Development
Mr. David Chien
Show Less

See Also

Discover More
What is the Intrinsic Value of one KRYS stock?

The intrinsic value of one KRYS stock under the Base Case scenario is 113.67 USD.

Is KRYS stock undervalued or overvalued?

Compared to the current market price of 190.4 USD, Krystal Biotech Inc is Overvalued by 40%.

Back to Top